Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Developments in the management of autosomal dominant polycystic kidney disease

Authors Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Published 11 April 2008 Volume 2008:4(2) Pages 393—407

DOI https://doi.org/10.2147/TCRM.S1617

Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Department of Medicine, Health Sciences Center, University of Colorado School of Medicine, Denver, CO 80262, USA

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent life- threatening, hereditary disease. ADPKD is more common than sickle cell anemia, cystic fibrosis, muscular dystrophy, hemophilia, Down’s syndrome, and Huntington’s disease combined. ADPKD is a multisystemic disorder characterized by the progressive development of renal cysts and marked renal enlargement. Structural and functional renal deterioration occurs in ADPKD patients and is the fourth leading cause of end-stage renal disease (ESRD) in adults. Aside from the renal manifestations, extrarenal structural abnormalities, such as liver cysts, cardiovascular abnormalities, and intracranial aneurysms may lead to morbidity and mortality. Recent studies have identified prognostic factors for progressive renal impairment including gender, race, age, proteinuria, hematuria, hypertension and increased left ventricular mass index (LVMI). Early diagnosis and better understanding of the pathophysiology of the disease provides the opportunity to aggressivly treat hypertension with renin-angiotensin-aldosterone system inhibitors and thereby potentially reduce LVMI, prevent cardiovascular morbidity and mortality and slow progression of the renal disease.

Keywords: hypertension, liver cysts, renal pain, left ventricular hypertrophy, cerebral aneurysms

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The diagnostic value of endothelial function as a potential sensor of fatigue in health

Yoshiko Ohno, Teruto Hashiguchi, Ryuichi Maenosono, et al

Vascular Health and Risk Management 2010, 6:135-144

Published Date: 9 March 2010

Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique

Peter Brand, Bettina Hederer, George Austen, Helen Dewberry, Thomas Meyer

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:763-770

Published Date: 5 December 2008

The renin–angiotensin system and diabetes: An update

Antônio Ribeiro-Oliveira Jr, Anelise Impeliziere Nogueira, Regina Maria Pereira, Walkiria Wingester Vilas Boas, Robson Augusto Souza dos Santos, Ana Cristina Simões e Silva

Vascular Health and Risk Management 2008, 4:787-803

Published Date: 8 August 2008

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Therapeutics and Clinical Risk Management 2008, 4:821-826

Published Date: 8 August 2008

Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria

Elmir Omerovic, Gerhard Brohall, Markus Müller, Truls Råmunddal, Göran Matejka, et al

Therapeutics and Clinical Risk Management 2008, 4:705-711

Published Date: 8 August 2008

Genetics of chronic obstructive pulmonary disease

Carola Seifart, Alexandra Plagens

International Journal of Chronic Obstructive Pulmonary Disease 2007, 2:541-550

Published Date: 15 January 2008

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008

The renaissance of fixed dose combinations: Combivir

Simon D Portsmouth, Christopher J Scott

Therapeutics and Clinical Risk Management 2007, 3:579-583

Published Date: 15 September 2007